FOXO4-DRI Dosage: Common Protocol, Mouse Data and Calculator
No human trial has ever given anyone FOXO4-DRI. The only real dosing figures are from the 2017 mouse study: 5 mg/kg, three times, every other day.
The short version
No published human trial has given anyone FOXO4-DRI, so there is no trial-established dose. Reported protocols vary more than for most compounds on this site. They run roughly 0.25-5 mg by subcutaneous injection, some daily, others three to five days a week, in blocks of 2 to 16 weeks. These are common practice, not a tested or approved dose. The only trial-grade numbers are from the original 2017 mouse study.
- No published human trial has injected FOXO4-DRI into anyone, at any dose.
- Reported protocols vary widely: roughly 0.25-5 mg SC, some protocols daily, others three to five days a week - common practice, not trial data.
- The only trial-grade numbers come from a 2017 mouse study: 5 mg/kg x 3, every other day.
- That mouse dose is not converted into a human figure anywhere on this page.
No published human study has given anyone an injection of FOXO4-DRI, so nothing below is a trial-established dose. What follows is the protocol most often used in practice, sourced to the vendors and community guides that publish it. Next to it are the only trial-grade numbers that exist, from the original 2017 mouse study. For the fuller research record and legal status, see the main FOXO4-DRI guide.
US legal status - Research use only
FOXO4-DRI has no FDA-approved product and no dose established by any regulator or trial. It does not appear in FDA's Category 2 or withdrawn-nominations tables for compounding, and it is sold to consumers as a research chemical.
FOXO4-DRI dosage: the common protocol
Reported protocols vary more here than for most compounds on this site. Sources describe roughly 0.25-5 mg by subcutaneous injection, some protocols daily, others three to five days a week. Blocks run anywhere from 2 to 16 weeks, with a long break of roughly 12-26 weeks reported between them. This is common practice reported by vendors and community guides, not a dose any trial has tested.
Common protocol
What is commonly used, not a dose established in trials. No regulator has set a dose for FOXO4-DRI. Sources differ, so the ranges below span them.
- Dose per administration
- 0.25-5 mg
- How often
- reported protocols vary widely - some use daily dosing, others 3 to 5 days a week in short blocks
- Route
- Subcutaneous injection
- Cycle length
- 2-16 weeks
- Break between cycles
- 12-26 weeks
- Common vial size
- 10 mg
- Timing
- Often taken in the morning
Sources disagree more here than for most compounds on this site: one describes a 16-week daily microgram-range escalation, another a 3-times-weekly milligram protocol with 8 weeks on and 12-16 off, and a third a 1 mg, 5-days-on/2-off block run only 2-3 times a year with 3-6 months between courses. The ranges above span all three rather than picking one. The 10 mg vial size is the one figure all three sources agree on.
Plan a cycle in the protocol builder or work out injection volume in the dosage calculator.
The common FOXO4-DRI dose is 0.25-5 mg, reported protocols vary widely - some use daily dosing, others 3 to 5 days a week in short blocks. From a 10 mg vial mixed with 2 mL of bacteriostatic water, 2.5 mg is 50 units (0.5 mL) on a U-100 insulin syringe.
FOXO4-DRI 10 mg vial: units per dose
Full 10 mg vial page: mixing, doses per vial, how long it lasts →
| Water added | Concentration | 1 unit = | 250 mcg | 2.5 mg | 5 mg |
|---|---|---|---|---|---|
| 1 mL | 10 mg/mL | 100 mcg | 2.5 units | 25 units | 50 units |
| 2 mL | 5 mg/mL | 50 mcg | 5 units | 50 units | 100 units |
| 3 mL | 3.33 mg/mL | 33.33 mcg | 7.5 units | 75 units | over 100 units |
All FOXO4-DRI vial sizes: 10 mg
Units are on a standard U-100 insulin syringe (100 units = 1 mL), rounded to the nearest half unit - half-unit marks are on 0.3 mL syringes. Water volumes are examples: more water means more units per dose, not more doses per vial. For any other vial or dose, use the calculator below.
How many 10 mg vials a cycle takes
| Scenario | Dose | Doses a week | Weeks | Total | 10 mg vials |
|---|---|---|---|---|---|
| Low end of the common protocol | 250 mcg | 3 | 2 | 1.5 mg | 1 |
| High end of the common protocol | 5 mg | 7 | 16 | 560 mg | 56 |
Whole vials, rounded up. Plan a cycle with your own numbers in the protocol builder. Keep mixed vials cold and use them within the window in how long reconstituted peptides last; where to inject: subcutaneous injection sites.
What the human record contains: nothing
As the main guide documents, a PubMed search for FOXO4-DRI returns 19 records, and none is indexed under a clinical-trial publication type. None of them gave FOXO4-DRI to a person. There is no low dose, no conservative starting dose and no “researchers typically use” figure to report, because none has been published.
Doses used in animal studies
The 2017 paper that first described FOXO4-DRI Baar 2017 - Baar MP, Brandt RMC, Putavet DA et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16., in the references below used the same regimen in every experiment: three injections of 5 mg/kg, every other day.
| What was tested | Mice | Dose | Route | Schedule |
|---|---|---|---|---|
| Doxorubicin chemotoxicity | Standard lab mice given doxorubicin | 5 mg/kg per injection | Intravenous | 3 injections, every other day (days 1, 3, 5) |
| Fast-aging (XpdTTD/TTD) mice | Progeroid XpdTTD/TTD mice | 5 mg/kg per injection | Intravenous | 3 injections, every other day |
| Naturally aged mice (110+ weeks) | Aged p16-3MR mice | 5 mg/kg per injection | Intravenous, with an intraperitoneal comparison arm | 3 injections, every other day |
The paper did not vary the dose to find a minimum or maximum effective amount in any of these models.
What is not established
- No human dose exists, at any amount, route, frequency or duration, because no published study has given FOXO4-DRI to a person.
- No human half-life is established. Neither this page nor the main guide states one, and none should be assumed for spacing doses.
- No human safety threshold is established. The mouse study reports the regimen was “well tolerated” in the mice it studied. That describes mice under monitored laboratory conditions, not a human safety finding.
- The common protocol above is not trial-established. It reflects what vendors and community guides report using, not a dose any completed trial has tested or any regulator has reviewed. Those sources also disagree with each other more than for most compounds on this site.
How to reconstitute FOXO4-DRI
The injection volume for a target amount depends on a specific vial’s concentration and diluent, which this page cannot know. Working out that arithmetic changes nothing about the fact that no human dose is established. The dosage calculator handles concentration and draw-volume math; it does not supply or endorse a dose.
Who should not use it
No FDA-reviewed contraindication list exists, because FOXO4-DRI has never gone through that review. There is no published human safety data on pregnancy, breastfeeding, children, drug interactions, or use alongside any diagnosed condition. That includes the cancers and chemotherapy exposures the mouse work was modeling.
FOXO4-DRI side effects and risks
The central risk is the size of the gap in the data. No human trial has given FOXO4-DRI to anyone, so there is no human safety profile, half-life or dose. The peptide is meant to kill senescent cells and spare healthy ones, and that selectivity is the whole premise for using it. It has only been shown in cells and mice, never confirmed in a person. Material sold as a research chemical also carries no regulator-verified purity, identity or concentration.
Related
FOXO4-DRI dosage calculator
Preset to a 10 mg vial and 250 mcg, the low end of the common protocol. Enter your own vial size, water and dose to get the syringe units to draw.
Your vial
Printed on the vial. There is no standard size - enter what yours says.
This changes how much you draw - never how many doses the vial holds.
100 units per mL. 1 unit = 0.01 mL. This is what almost every insulin syringe sold is, in every barrel size.
Capacity only. A 1 mL U-100 syringe holds 100 units - the scale decides that, not the barrel.
Draw this much
= 0.05 mL on a 1 mL U-100 syringe
- Concentration
- 5,000 mcg/mL
- Exact volume
- 0.05 mL
- Dose you actually get
- 250 mcg
- Doses per vial(unaffected by water volume)
- 40
Where to buy FOXO4-DRI for research
Each vendor is checked against my vendor checklist.
1.BioEdge Research Labs
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
Common questions
What is the usual FOXO4-DRI dose?
No published human trial has tested a dose, so nothing here is trial-established. Sources describe roughly 0.25-5 mg by subcutaneous injection, some protocols daily, others three to five days a week. Blocks run 2 to 16 weeks, with a reported break of roughly 12-26 weeks between them. This is common practice, not a tested or approved dose, and sources disagree more than for most compounds on this site.
What dose did the original FOXO4-DRI study use?
The 2017 paper that first described FOXO4-DRI gave mice three injections of 5 mg/kg, every other day, by intravenous or intraperitoneal injection depending on the experiment. That is a mouse dose from specific experiments, not a human protocol.
Can the mouse dose be converted into a human dose?
Not reliably, and this page does not try. Body-surface-area conversion formulas exist for early drug development, but using one here would create a precise-looking human number for a compound that no published human trial has dosed.
How do I work out reconstitution and injection volume?
That is arithmetic about a specific vial and diluent, not a dosing decision. It does not change the fact that no human dose is established. The dosage calculator handles concentration and draw-volume math for whatever amount is being discussed; it does not supply or endorse a dose.
Who should not use FOXO4-DRI, and what are the risks?
With no published human study, there is no regulator-reviewed contraindication list. There is also no human safety data on pregnancy, interactions or long-term use. Material sold as a research chemical carries no regulator-verified purity, identity or concentration.
References (1 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.